



Flutisal® 100 ConviCap: Each capsule contains Fluticasone Propionate BP 100 µg and Salmeterol Xinafoate BP equivalent to 50 µg Salmeterol inhalation powder.

Flutisal® 250 ConviCap: Each capsule contains Fluticasone Propionate BP 250 µg and Salmeterol Xinafoate BP equivalent to 50 µg Salmeterol inhalation powder.

Flutisal® 500 ConviCap: Each capsule contains Fluticasone Propionate BP 500 µg and Salmeterol Xinafoate BP equivalent to 50 µg Salmeterol inhalation powder.

Fluticasone Propionate, corticosteroid having the chemical name S-(fluoromethyl) 6a, 9-difluoro-11 β , 17-dihydroxy-16 α -methyl-3-oxoandrosta-1, 4-diene-17 β -carboate, 17 β -propionate. Fluticasone Propionate is a white powder with a molecular weight of 506.6 and the empirical formula is C₂₅H₃₄F₆O₅. It is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol. Salmeterol Xinafoate, a β_2 -adrenergic bronchodilator. The chemical name of Salmeterol Xinafoate is 4-hydroxy- α -[[(6-(4-phenyl)butoxy)hexyl]amino]methyl]-1, 3-benzenedimethoxy-1, 4-hydroxy-2-naphthalenecarboxylate.

Treatment of asthma: Fluticasone Propionate & Salmeterol Xinafoate combination is indicated for the treatment of asthma in patients aged 4 years and older. It is indicated for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. It is not indicated for the relief of acute bronchospasm.

Rinsing the mouth after each inhalation is advised

The common side effects experienced are oral candidiasis, pneumonia, immunosuppression/hypocorticism, adrenal suppression, growth retardation, glaucoma and cataracts etc. The few side effects have been reported infrequently like ear signs and symptoms; nasal signs and symptoms; nasal sinus disorders; keratitis and conjunctivitis; dental discomfort and pain; gastrointestinal signs and symptoms; oral ulcerations; oral discomfort and pain; lower respiratory signs and symptoms; muscle stiffness, tightness, and rigidity; bone and cartilage disorders; sleep disorders; compressed nerve syndromes; chest symptoms; fluid retention; unusual taste; viral skin infections; disorders of sweat and sebum.

3) Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infections of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

where intensive measures are required.

The use of strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with Fluticasone Propionate & Salmeterol Xinafoate combination is contraindicated because increased systemic corticosteroid and increased cardiovascular adverse effects may occur. Ketoconazole, beta-adrenergic receptor blocking agents and nonpotassium-sparing diuretics are also contraindicated.

Commercial Pack

Flutisal[®] 500 ConviCap: Each box contains 5 alu-alu blister strips of 6 capsules